Literature DB >> 9473282

Quantitation of proteoglycans as glycosaminoglycans in biological fluids using an alcian blue dot blot analysis.

S Björnsson1.   

Abstract

A method for quantitation of intact proteoglycans as GAGs in biological fluids (blood plasma, synovial fluid) or 4 M guanidine extracts of tissues has been published previously (S. Björnsson, Anal. Biochem. 210, 282-291, 1993). The method is based on the specific interaction between sulfated polymers and the tetravalent cationic dye Alcian blue at pH 1.5 in 0.4 M guanidine-HCl and in the presence of 0.25% Triton. The absorbance assay has a measuring range of 1-20 microgram of glycosaminoglycan (GAG) which is not sensitive enough to measure the low contents of proteoglycans in blood plasma, urine, or wound fluid. A dot blot assay is now described in which the Alcian blue-GAG complexes are collected on a polyvinylidene fluoride membrane, by filtration in a dot blot apparatus, and the stain is quantitated as reflectance by scanning and densitometry. The assay requires 10 microliter of sample and has a measuring range of 10-800 ng of GAG, corresponding to a concentration of 1-80 mg/liter, suitable for proteoglycans in biological fluids. The procedures for chemistry, scanning, densitometry, and curve fitting were each evaluated separately. The error contributed by chemistry accounted for a minor portion of the imprecision. The imprecision contributed by scanning was the most important source of within-run and between-run imprecision, and was caused by inequalities of the charge-coupled device along the scanning arm. Unexpectedly, curve fitting was also a major source of total imprecision in dot blot quantitation and differed with the type of equation used. The between-run imprecision calculated as CV (SD/mean . 100) was 13.0% at 8 mg/liter. The response of the assay was identical for six different commercial preparations of GAGs (chondroitin-4-sulfate, chondroitin-6-sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, and heparin) despite differences in degree of sulfation known to exist. There was no positive or negative interference by blood plasma, apart from a slight negative interference on the quantitation of heparan sulfate. Analysis of 319 paired blood plasma and urine specimens from hospitalized patients showed a variation of plasma GAGs of 0.1-17.6 and urine-GAGs of 0.0-45.6 mg/liter. There was no correlation between plasma and urine GAG concentrations. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9473282     DOI: 10.1006/abio.1997.2494

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  21 in total

1.  Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis.

Authors:  Sassan HajMohammadi; Keiichi Enjyoji; Marc Princivalle; Patricia Christi; Miroslav Lech; David Beeler; Helen Rayburn; John J Schwartz; Samad Barzegar; Ariane I de Agostini; Mark J Post; Robert D Rosenberg; Nicholas W Shworak
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

2.  BMP-2 and TGF-β3 do not prevent spontaneous degeneration in rabbit disc explants but induce ossification of the annulus fibrosus.

Authors:  Daniel Haschtmann; Stephen J Ferguson; Jivko V Stoyanov
Journal:  Eur Spine J       Date:  2012-05-26       Impact factor: 3.134

3.  The Quantification of Glycosaminoglycans: A Comparison of HPLC, Carbazole, and Alcian Blue Methods.

Authors:  Sarah B Frazier; Kevin A Roodhouse; Dennis E Hourcade; Lijuan Zhang
Journal:  Open Glycosci       Date:  2008-01-01

4.  Role for 3-O-sulfated heparan sulfate as the receptor for herpes simplex virus type 1 entry into primary human corneal fibroblasts.

Authors:  Vaibhav Tiwari; Christian Clement; Ding Xu; Tibor Valyi-Nagy; Beatrice Y J T Yue; Jian Liu; Deepak Shukla
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

5.  Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.

Authors:  Francyne Kubaski; Yasuyuki Suzuki; Kenji Orii; Roberto Giugliani; Heather J Church; Robert W Mason; Vũ Chí Dũng; Can Thi Bich Ngoc; Seiji Yamaguchi; Hironori Kobayashi; Katta M Girisha; Toshiyuki Fukao; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-12-22       Impact factor: 4.797

Review 6.  Glycosaminoglycans detection methods: Applications of mass spectrometry.

Authors:  Francyne Kubaski; Harumi Osago; Robert W Mason; Seiji Yamaguchi; Hironori Kobayashi; Mikako Tsuchiya; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-09-28       Impact factor: 4.797

Review 7.  Newborn screening of mucopolysaccharidoses: past, present, and future.

Authors:  Nivethitha Arunkumar; Thomas J Langan; Molly Stapleton; Francyne Kubaski; Robert W Mason; Rajendra Singh; Hironori Kobayashi; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji Orii; Tadao Orii; Toshiyuki Fukao; Shunji Tomatsu
Journal:  J Hum Genet       Date:  2020-04-10       Impact factor: 3.172

Review 8.  Advances in glycosaminoglycan detection.

Authors:  Shaukat A Khan; Robert W Mason; Hironori Kobayashi; Seiji Yamaguchi; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2020-03-27       Impact factor: 4.797

9.  Human follicular fluid heparan sulfate contains abundant 3-O-sulfated chains with anticoagulant activity.

Authors:  Ariane I de Agostini; Ji-Cui Dong; Corinne de Vantéry Arrighi; Marie-Andrée Ramus; Isabelle Dentand-Quadri; Sébastien Thalmann; Patricia Ventura; Victoria Ibecheole; Felicia Monge; Anne-Marie Fischer; Sassan HajMohammadi; Nicholas W Shworak; Lijuan Zhang; Zhenqing Zhang; Robert J Linhardt
Journal:  J Biol Chem       Date:  2008-07-31       Impact factor: 5.157

10.  Endothelial cell capture of heparin-binding growth factors under flow.

Authors:  Bing Zhao; Changjiang Zhang; Kimberly Forsten-Williams; Jun Zhang; Michael Fannon
Journal:  PLoS Comput Biol       Date:  2010-10-28       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.